Pharmacological interventions for treatment-resistant depression in adults: a Cochrane Review

2021 ◽  
Vol 28 (1) ◽  
pp. 2-3
Author(s):  
Philippa Davies ◽  
Sharea Ijaz ◽  
Catherine J. Williams ◽  
David Kessler ◽  
Glyn Lewis ◽  
...  
1988 ◽  
Vol 33 (9) ◽  
pp. 788-792 ◽  
Author(s):  
G. William Macewan ◽  
Ronald A. Remick

One hundred and fourteen patients with a diagnosis of “treatment resistant depression” (TRD) were assessed and treated at a Mood Disorders Clinic. Diagnostically, 52 (45.6%) subjects met criteria for bipolar disorder, 49 (42.9%) for recurrent depression, and 13 (11.4%) patients did not fulfill diagnostic criteria for affective disorder which explained their treatment resistance. With appropriate, individualized treatment, 59 of 98 (60.2%) patients had complete symptom remission based on clinical and psychometric ratings (initial Ham-D 26.7, final Ham-D 5.9). Eighteen of 98 patients had partial remission (final Ham-D 15.9) with vigorous pharmacological interventions, and 8 subjects exhibited “absolute” TRD (final Ham-D 23.4). The results suggest the value of specialized mood disorder services. The partial and absolute TRD's were more likely to be older, received more Axis II diagnoses, and had previous histories of drug or alcohol abuse.


2020 ◽  
Vol 26 (5) ◽  
pp. 254-254
Author(s):  
Sharea Ijaz ◽  
Philippa Davies ◽  
Catherine J. Williams ◽  
David Kessler ◽  
Glyn Lewis ◽  
...  

2021 ◽  
Vol 28 (1) ◽  
pp. 4-8
Author(s):  
Chloe Wigg ◽  
Sara Costi

SUMMARYThe Cochrane review by Davies et al aimed to address the lack of clarity on the risks and benefits of switching and augmentation strategies in the pharmacological treatment of treatment-resistant depression in adults who did not respond (or partially responded) to at least 4 weeks of antidepressant treatment at a recommended dose. This commentary assesses their review and their conclusion that augmenting the current antidepressant with mianserin or with an antipsychotic improves depressive symptoms over the short-term (8 to 12 weeks). Their results need to be treated with caution owing to the small body of evidence and individual comparisons supported by one, two or three studies, the limited evidence on long-term effects and the significant gaps in the literature (e.g. a lack of studies assessing dose increases).


Sign in / Sign up

Export Citation Format

Share Document